文献速递其他结缔组织病

托法替布剂量递增治疗难治性抗MDA5抗体阳性皮肌炎的疗效与安全性

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.
PubMed 文献 · RMD Open · 2023-01-01

本病例系列报告6例抗MDA5抗体阳性皮肌炎合并快速进展性间质性肺病患者,因对三联疗法及托法替布10 mg/天反应不佳,将托法替布增至20 mg/天后4例改善、2例死亡;全部6例均发生至少一种感染,提示剂量递增可作为难治患者的选项但需权衡感染风险。

要点

  • 6例MDA5-DM合并RP-ILD患者因对三联疗法及托法替布10 mg/天反应不佳,将托法替布增至20 mg/天后4例改善、2例死亡。
  • 全部6例发生至少一种感染,包括5例巨细胞病毒再激活、1例肺曲霉病、1例带状疱疹和1例单纯疱疹性角膜炎。
  • 作者认为托法替布剂量递增可作为对10 mg/天托法替布及其他免疫抑制剂难治的MDA5-DM患者的选项,但需逐例仔细评估风险获益平衡。

核心结论

  • 作者认为,对托法替布10 mg/天及其他免疫抑制剂难治的MDA5-DM患者,托法替布剂量递增可作为一个选项,但感染风险值得关注。
  • 作者建议应逐例仔细评估托法替布剂量递增的风险获益平衡。

研究设计与样本

  • 本病例系列报告6例抗MDA5抗体阳性皮肌炎合并快速进展性间质性肺病患者,因对三联疗法(大剂量糖皮质激素、环磷酰胺和他克莫司)及托法替布10 mg/天反应不佳,将托法替布剂量从10 mg增至20 mg/天,随后再以托法替布10 mg/天治疗。

主要发现

  • 6例患者中4例在托法替布剂量递增后改善,2例无应答者死亡。
  • 全部6例患者均发生至少一种感染,包括5例巨细胞病毒再激活、1例肺曲霉病、1例带状疱疹和1例单纯疱疹性角膜炎。

关键数值与推荐

  • 托法替布剂量从10 mg/天增至20 mg/天,随后为托法替布10 mg/天。
  • 6例中4例改善,2例无应答者死亡。
  • 感染事件:5例巨细胞病毒再激活、1例肺曲霉病、1例带状疱疹、1例单纯疱疹性角膜炎。

临床怎么用

  • 作者认为托法替布剂量递增可作为对10 mg/天托法替布及其他免疫抑制剂难治的MDA5-DM患者的选项。
  • 作者指出感染风险值得关注,应逐例仔细评估托法替布剂量递增的风险获益平衡。

局限性

  • 原文指出既往那些疗法的疗效仅与历史对照进行比较。
  • 原文指出即使接受那些疗法,仍存在难治性患者。
  • 原文指出感染风险值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is frequently complicated with rapidly progressive-interstitial lung disease (RP-ILD). The prognosis of MDA5-DM with RP-ILD is mostly poor despite intensive treatment with a combination of high-dose glucocorticoids and single conventional immunosuppressants. It was reported that the triple therapy (high-dose glucocorticoids, cyclophosphamide and tacrolimus) was more effective than a combination of high-dose glucocorticoids and stepwise addition of immunosuppressants. In addition, the efficacy of tofacitinib 10 mg/day for MDA5-DM with RP-ILD refractory to the triple therapy was suggested. However, the effect of those therapies was evaluated only in comparison to the historical control. Moreover, more importantly, there are still refractory patients even if treated with those therapies. In this case series, we report six MDA5-DM cases with RP-ILD in which the dose of tofacitinib was increased from 10 mg to 20 mg/day due to poor response to the triple therapy, followed by tofacitinib 10 mg/day. Four of six patients improved after dose escalation of tofacitinib, while two non-responders died. All six patients developed at least one infection including five cases of cytomegalovirus reactivation, one pulmonary aspergillosis, one herpes zoster and one herpes simplex keratitis. These cases suggest that the dose escalation of tofacitinib can be an option for MDA5-DM patients refractory to 10 mg/day of tofacitinib and other immunosuppressants although the risk of infection is a concern. The risk-benefit balance of the dose escalation of tofacitinib should be carefully assessed in each case.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ida T, Furuta S, Takayama A, et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. 2023. PMID: 36593080. doi:10.1136/rmdopen-2022-002795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。